BPC-157 Peptide: From Drug Candidate to Rat Tendon Studies
Written bySpartan Research Team
- A stomach peptide that doesn’t fall apart. BPC-157 is a 15-amino-acid peptide with a molecular weight of 1,419 Da (Staresinic et al., 2003).Rat injury models carry the evidence.
- In rats it improved healing of cut tendon, then cut muscle and damaged ligament in later studies.One network did most of the work.
- Nearly all the core studies come from a closely connected group of Croatian researchers.
- The FDA flagged a data gap. A 2026 FDA briefing found too little clinical safety information to characterize it (FDA, 2026).
What is BPC-157?
BPC-157, often searched as bpc157, is a 15-amino-acid peptide that its developers describe as a stable gastric pentadecapeptide. The name stands for Body Protection Compound.
Its developers say it was derived from a protein found in gastric juice. The sequence they settled on has one notable property in the test tube: in an assay using gastric juice, it stayed intact for more than 24 hours, where gastric enzymes break many peptides down (Krivic et al., 2006).
That chemical stability is a big reason the group kept studying it. It’s also where the name comes from.
It was once a drug candidate, too. It carried the Croatian pharmaceutical company Pliva’s development code, PL 14736 (Staresinic et al., 2003), but it never reached approval.
BPC-157 profile
| Feature | BPC-157 |
|---|---|
| Sequence | Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val (GEPPPGKPADDAGLV) |
| Length | 15 amino acids (a pentadecapeptide) |
| Molecular weight | 1,419 Da |
| Other names | Body Protection Compound 157, PL 14736 |
| Main research areas | Tendon, muscle and ligament injury models in rats |
| Evidence base | Mostly rat studies from one research network |
| Regulatory status | Not approved by the FDA for any use |
What does BPC-157 do in research?
In rat injury models, BPC-157 improved healing of cut tendons, muscle and ligaments, judged by strength, function and tissue structure. Almost all of that work comes from one group, which matters as much as the results.
The Achilles tendon study
The most-cited BPC-157 study cut clean through the Achilles tendon in rats, leaving a gap between the two ends. A tendon doesn’t easily bridge a gap like that on its own, which makes it a demanding model.
Rats given BPC-157 did better on almost every measure. Their tendons held more load before failing, they scored higher on a walking-function index, and under the microscope the repair showed more fibroblasts and collagen with smaller defects (Staresinic et al., 2003).
More brake than accelerator
The cell-culture half of that paper is easy to skip. On its own, BPC-157 didn’t make cultured tendon cells divide, but it did counter a molecule that normally holds their growth back (Staresinic et al., 2003).
A growth factor such as TGF-beta drives cultured cells to divide by itself. BPC-157 didn’t, which suggests it isn’t simply one more growth factor.
One observation in a dish doesn’t settle a mechanism. It does tell researchers which question to ask next, and it’s a reminder that a healing result in an animal says nothing about how the effect happened.
Tendon-to-bone healing
A 2006 follow-up made the injury harder. Instead of cutting the tendon, researchers detached it from the heel bone, a junction that doesn’t reattach on its own in that model (Krivic et al., 2006).
They reported better tendon-to-bone healing with BPC-157. Some rats also received a corticosteroid, which made healing worse, and BPC-157 reduced that worsening (Krivic et al., 2006).
Muscle and ligament models
Muscle came next. In rats with a fully cut quadriceps, a defect that normally can’t be compensated, BPC-157 improved healing across a 72-day study, with function restored (Staresinic et al., 2006).
A 2010 paper then reported improved ligament healing in rats (Cerovecki et al., 2010). That made three kinds of connective tissue in the same research program.
BPC-157 rat studies by injury model
| Injury model | Main readouts | Source |
|---|---|---|
| Cut Achilles tendon | Load to failure, walking index, collagen | Staresinic et al., 2003 |
| Tendon detached from bone | Tendon-to-bone healing, steroid effect | Krivic et al., 2006 |
| Cut quadriceps muscle | Healing and function over 72 days | Staresinic et al., 2006 |
| Damaged ligament | Ligament healing | Cerovecki et al., 2010 |
Three readouts in every study
Most BPC-157 papers follow one design. They create a defined injury in rats, follow BPC-157 groups and controls for weeks, and score the result three ways: mechanical strength, walking function and appearance under the microscope.
That triple readout is a real strength. A result that shows up in strength, function and structure at once is harder to explain away than a single number.
Why so much of it comes from one place
The studies above share overlapping authors from one Croatian research network, and the 2010 ligament paper still carries Pliva’s development code, PL 14736, in its title. Most popular BPC-157 coverage skips that context.
None of this makes the findings wrong. Plenty of fields start with a single group, but it does mean replication by unconnected labs is the most useful thing a reader can look for.
Four checks for a BPC-157 paper
- Match the claim to the injury. A cut tendon, a detached tendon, a cut muscle and a damaged ligament are different problems.
- Look at all three readouts. Strength, function and microscopic structure answer different questions, and the strongest results move all three.
- Find the control group. BPC-157 rats should be compared with rats that had the same injury and the same handling.
- Read the author list. Note whether the authors overlap with the original network, since independent labs carry extra weight.
BPC-157 and TB-500
BPC-157 is often studied alongside TB-500, and the pairing is common enough to have its own name, covered in the guide to the Wolverine stack.
The two have little in common chemically. BPC-157 is a gastric peptide, while TB-500 is linked to thymosin beta-4, an actin-binding protein, and some TB-500 material is only a seven-residue piece of it, explained in the TB-500 peptide guide.
BPC-157 also turns up in combination research with the GHK-Cu peptide, and with thymosin alpha-1 in the immune support research stack.
Is BPC-157 FDA approved?
No. There’s no approved BPC-157 drug, and the FDA hasn’t approved it for any use.
In 2026 the FDA reviewed it for possible use in pharmacy compounding. Its briefing document stated there is insufficient clinical safety information to characterize the safety profile of BPC-157 (FDA, 2026).
Keeping BPC-157 stable in the lab
Gastric stability is a property of the molecule, not a pass on careful storage. Sealed lyophilized vials still go somewhere cold, dry and dark, as the batch certificate specifies.
Record lot numbers and receipt dates for every vial. When two experiments disagree, the lot is the first thing to compare.
What a BPC-157 certificate should show
The sequence is short and well defined, so a certificate of analysis can confirm it cleanly.
- Identity by mass spectrometry, matching a mass of about 1,419 Da for the 15-residue chain.
- Purity by HPLC, stated as a percentage of the main peak.
- A matching lot number, identical on the certificate and the vial label.
Spartan publishes the BPC-157 certificate of analysis for the current lot. You’ll find BPC-157 5mg research vials on the product page.
Where BPC-157 research stands
BPC-157 is a stable 15-amino-acid gastric peptide that began as a drug candidate. In rats it improved healing of cut tendons, detached tendons, cut muscle and damaged ligaments, measured by strength, function and structure.
Nearly all of that comes from one network, and the FDA’s 2026 review found too little clinical safety information to characterize it. Read the studies as a consistent rat-model story that still needs independent confirmation.
BPC-157 FAQ
What is BPC-157?
BPC-157 is a synthetic 15-amino-acid peptide, GEPPPGKPADDAGLV, described by its developers as a stable gastric pentadecapeptide. It’s studied in rat injury models and sold for laboratory research use only.
What does BPC-157 stand for?
Body Protection Compound 157. It also carried the development code PL 14736 from the Croatian pharmaceutical company Pliva, as a drug candidate that never reached approval.
What does BPC-157 do in rat studies?
In rats, it improved healing of cut and detached Achilles tendons, cut quadriceps muscle and damaged ligaments, measured by strength, walking function and tissue structure. These are animal-model findings.
Is BPC-157 a peptide?
Yes. BPC-157 is a pentadecapeptide, a chain of 15 amino acids, with a molecular weight of about 1,419 Da. Research material is made synthetically from the published sequence.
Is BPC-157 FDA approved?
No. BPC-157 isn’t approved by the FDA for any use. A 2026 FDA briefing document stated there is insufficient clinical safety information to characterize its safety profile.
Why is BPC-157 called a stable gastric pentadecapeptide?
Its developers coined the phrase. “Gastric” refers to the protein it was derived from, “pentadecapeptide” to its 15 amino acids, and “stable” to an in-vitro assay in which the sequence stayed intact for more than 24 hours.
Who discovered BPC-157?
Croatian researchers working with the pharmaceutical company Pliva developed it as PL 14736, and most published BPC-157 studies, including the main rat tendon and muscle work, still come from that same research network.
Research use disclaimer. All content published by Spartan Peptides is for educational and research purposes only. It is not medical advice and is not a recommendation for human use. Products sold on this site are research compounds intended for laboratory and in vitro applications only.
Written by the Spartan Research Team
Our team of peptide researchers and biochemists reviews every article for scientific accuracy. Learn more about our team →